Skip to content
    Clinical Trials

    DESTINY-Lung06: Phase III Trial of Trastuzumab Deruxtecan Plus Pembrolizumab in NSCLC

    Jänne et alFuture oncology (London, England)

    DESTINY-Lung06: Phase III Trial of Trastuzumab Deruxtecan Plus Pembrolizumab in NSCLC
    Human epidermal growth factor receptor 2 (HER2) overexpression in non-small cell lung cancer (NSCLC) is associated with poor prognosis, and no HER2-targeted therapies are currently approved for HER2-overexpressing NSCLC in the first-line setting. Although pembrolizumab combined with pemetrexed and platinum-based chemotherapy is a standard first-line regimen for nonsquamous NSCLC without actionable driver mutations, clinical outcomes with pembrolizumab-based regimens correlate with higher programmed death-ligand 1 (PD-L1) expression levels. Consequently, patients with lower PD-L1 tumor proportion scores (TPS <50%) represent a population requiring more effective targeted treatment strategies.
    DESTINY-Lung06 (ClinicalTrials.gov identifier NCT06899126; EudraCT 2024-51) is a multicenter, open-label, randomized phase III trial evaluating the efficacy and safety of trastuzumab deruxtecan (T-DXd) plus pembrolizumab as first-line therapy in patients with HER2-overexpressing (≥25% moderate/strong membrane staining), PD-L1 TPS <50% NSCLC. The study will enroll approximately 686 patients randomized to receive either T-DXd 5.4 mg/kg with pembrolizumab 200 mg intravenously every 3 weeks (Q3W) or standard pembrolizumab 200 mg plus pemetrexed 500 mg/m² and platinum chemotherapy (cisplatin 75 mg/m² or carboplatin AUC 5) Q3W. Blinded independent central review-assessed progression-free survival serves as the primary endpoint, with overall survival designated as the key secondary endpoint.

    Key Takeaways

    • The phase III DESTINY-Lung06 trial (NCT06899126) is evaluating first-line trastuzumab deruxtecan plus pembrolizumab versus pembrolizumab with pemetrexed and platinum chemotherapy in approximately 686 patients with HER2-overexpressing (≥25% moderate/strong membrane staining), PD-L1 TPS <50% non-small cell lung cancer, with primary endpoint of progression-free survival by blinded independent central review.
    Read the original sourceFuture oncology (London, England)